Management of Glucagonoma

Anatomical Distribution and Surgical Treatment

The National Comprehensive Cancer Network recommends distal pancreatectomy with splenectomy and resection of peripancreatic lymph nodes for glucagonomas located in the tail of the pancreas, which is the most common site 1, 2
For glucagonomas in the head of the pancreas, the National Comprehensive Cancer Network recommends pancreatoduodenectomy with resection of peripancreatic lymph nodes 3
The National Comprehensive Cancer Network suggests enucleation or local excision with peripancreatic lymph dissection may be considered for small (<2 cm) peripheral glucagonomas 1

The National Comprehensive Cancer Network notes that a hypercoagulable state has been reported in patients with glucagonoma, which may necessitate perioperative anticoagulation 1, 3
Perioperative anticoagulation should be considered due to the increased risk of thromboembolism, as recommended by the National Comprehensive Cancer Network 1, 3

The National Comprehensive Cancer Network recommends that ductal adenocarcinomas, which occur in the pancreatic head in 80-90% of cases, be distinguished from glucagonomas in terms of location 4
The American Joint Committee on Cancer and other organizations support the notion that for the less common head location of glucagonomas, pancreatoduodenectomy (Whipple procedure) with peripancreatic lymph node resection is required, based on guidelines from the National Comprehensive Cancer Network 5

The National Comprehensive Cancer Network (NCCN) recommends surgical resection as the definitive therapy for glucagonoma, selecting the operative technique based on tumor location: distal pancreatectomy with splenectomy and peripancreatic lymph‑node dissection for lesions in the pancreatic tail (most common), and pancreatoduodenectomy (Whipple procedure) for lesions in the pancreatic head. 6

The NCCN advises that hyperglycemia and diabetes be optimized before surgery, employing measures such as intravenous fluid therapy to achieve glycemic control. 6, 7
The NCCN recommends initiating somatostatin analogues (octreotide or lanreotide) pre‑operatively for symptom control, noting that glucagonomas are generally sensitive to these agents. 8, 9
The NCCN suggests that total parenteral nutrition be considered pre‑operatively in patients with severe weight loss secondary to glucagonoma. 8

The NCCN mandates administration of the trivalent vaccine (pneumococcal, Haemophilus influenzae b, and meningococcal) to all patients undergoing splenectomy as part of glucagonoma surgery. 6, 7